Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

Blood (2024) 144 (16): 1722–1731.

https://doi.org/10.1182/blood.2024023840

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Blood (2023) 142 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2023-179171

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

Blood (2023) 142 (Supplement 1): 1538.

https://doi.org/10.1182/blood-2023-173092

Published: 2023

Journal Articles

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Blood (2023) 142 (Supplement 1): 4223.

https://doi.org/10.1182/blood-2023-189800

Published: 2023

Journal Articles

Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones

Blood (2023) 142 (Supplement 1): 2958.

https://doi.org/10.1182/blood-2023-188865

Published: 2023

Journal Articles

Germline Predisposition in Myeloid Neoplasms Aged ≥50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

Blood (2023) 142 (Supplement 1): 5663.

https://doi.org/10.1182/blood-2023-179234

Published: 2023

Journal Articles

Early-Onset Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) without SF3B1 Mutations in Adults: Enrichment with Germline Variants in Genes Responsible for Congenital Sideroblastic Anemias

Sandra Novoa Jáuregui, Tzu Chen, Sara Torres-Esquius, Salvador Carrillo-Tornel, Marta Santiago, Teresa Bernal Del Castillo, Francisca Maria Hernandez, Alessandro Liquori, Ivan Martin Castillo, Mar Tormo, Barbara Tazon, Adoracion Blanco, Laura Palomo, Jose Cervera, Francesc Bosch, David Valcarcel, Maria Diez-Campelo, Julia Montoro, Andres Jerez

Blood (2023) 142 (Supplement 1): 4610.

https://doi.org/10.1182/blood-2023-185836

Published: 2023

Journal Articles

Multiomics Characterization of Normal CD34+ Hematopoietic Progenitor Cells (HPC) and Blasts in the Bone Marrow (BM) and Peripheral Blood (PB) of Patients with Acute Myeloid Leukemia (AML)

Catia Simoes, Carmen Gonzalez, Leire Burgos, Sarai Sarvide, Diego Alignani, Aitziber Lopez, Ivan Quispe, Jose A. Pérez-Simón, María García-Fortes, Teresa Bernal Del Castillo, Mercedes Colorado, Teresa Olave, Ana Alfonso Pierola, Felipe Prosper, Pau Montesinos, Bruno Paiva

Blood (2023) 142 (Supplement 1): 2951.

https://doi.org/10.1182/blood-2023-185760

Published: 2023

Journal Articles

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2023-190128

Published: 2023

Journal Articles

ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder

Salvador Carrillo-Tornel, Tzu Hua Chen-Liang, Ana Yeguas Bermejo, Helena Pomares, Alessandro Liquori, Teresa González, Teresa Bernal del Castillo, Marta Santiago, Félix López Cadenas, Bernardo López Andrade, Raul Teruel Montoya, Esperanza Such, Francisca Maria Hernandez, Blanca Xicoy, Montserrat Arnan Sangerman, Francesc Solé, Jose Cervera, Maria Diez-Campelo, Andres Jerez

Blood (2022) 140 (Supplement 1): 4074–4075.

https://doi.org/10.1182/blood-2022-168759

Published: 2022

Journal Articles

Prognostic Impact of NPM1 and FLT3 -ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Blood (2022) 140 (Supplement 1): 6077–6079.

https://doi.org/10.1182/blood-2022-167365

Published: 2022

Journal Articles

Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Blood (2022) 140 (Supplement 1): 8919–8920.

https://doi.org/10.1182/blood-2022-162591

Published: 2022

Journal Articles

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Blood (2022) 140 (Supplement 1): 3438–3440.

https://doi.org/10.1182/blood-2022-160136

Published: 2022

Journal Articles

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Blood (2022) 140 (Supplement 1): 9100–9102.

https://doi.org/10.1182/blood-2022-163016

Published: 2022

Journal Articles

Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry

Blood (2021) 138 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2021-150544

Published: 2021

Journal Articles

Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Blood (2021) 138 (Supplement 1): 1256.

https://doi.org/10.1182/blood-2021-150649

Published: 2021

Journal Articles

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Blood (2021) 138 (Supplement 1): 3486.

https://doi.org/10.1182/blood-2021-148263

Published: 2021

Journal Articles

Germline and Somatic Variants Co-Ocurrence Profile in Early Onset Adult Myelodysplastic Syndromes without a Preexisting Disorder

Blood (2021) 138 (Supplement 1): 2595.

https://doi.org/10.1182/blood-2021-152128

Published: 2021

Journal Articles

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Blood (2021) 138 (Supplement 1): 2610.

https://doi.org/10.1182/blood-2021-152678

Published: 2021

Journal Articles

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Pilar Martínez, MD, Tomás Palanques Pastor, Jose Luiz Lopez Lorenzo, MD, Javier Cornago Navascués, MD, Gabriela Rodriguez-Macías, MD, Isabel Cano, MD, Montserrat Arnan Sangerman, María-Belén Vidriales, MDPhD, Jesús Lorenzo Algarra, Maria Angeles Foncillas, Pilar Herrera Puente, Carmen Botella, Susana Vives, MD, Angela Figuera Alvarez, MD PhD, Laida Cuevas Palomares, Marta Sobas, MDPhD, Alejandro Contento-Gonzalo, MD, Rebeca Cuello, MD, María Elena Amutio Diez, MD, Maria Dunia De Miguel, MD, Begoña Navas, MD, Juan Miguel Bergua Burgues, MD, Teresa Bernal del Castillo, MD PhD, María Carmen Mateos Rodríguez, MD, Erik de Cabo López, MD, Ana Carolina Franco Villegas, MD, Raimundo García-Boyero, MD, Cristian Escolano Escobar, MD, Cristina Seri, MD, Carlos Cervero, MD, Alicia Roldán Pérez, Maria Lourdes Hermosin, MD, Marta Cervera, MD, María Teresa Olave, MD, Paola Sandra Villafuerte Gutierrez, MD, Almudena De Laiglesia, MD, Josefina Serrano, MD, María Josefa Najera Irazu, MD, Jose Luis Piñana Sanchez, Miguel Ángel Sanz, MD, Joaquin Martinez-Lopez, MD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138471

Published: 2020

NARROW

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones

Germline Predisposition in Myeloid Neoplasms Aged ≥50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

Early-Onset Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) without SF3B1 Mutations in Adults: Enrichment with Germline Variants in Genes Responsible for Congenital Sideroblastic Anemias

Multiomics Characterization of Normal CD34+ Hematopoietic Progenitor Cells (HPC) and Blasts in the Bone Marrow (BM) and Peripheral Blood (PB) of Patients with Acute Myeloid Leukemia (AML)

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder

Prognostic Impact of NPM1 and FLT3 -ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry

Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Germline and Somatic Variants Co-Ocurrence Profile in Early Onset Adult Myelodysplastic Syndromes without a Preexisting Disorder

Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only